Page 207 - Aet News Today

CommonSpirit Health is facing a proposed class-action lawsuit over a ransomware attack it suffered last fall that exposed 623,774 patients' personal data. However, hospitals' data breach lawsuits usually never make it court, a legal expert said.

This is a reversal from several years ago, when more Medicare Advantage beneficiaries switched to traditional Medicare, a recent report found. Medicare Advantage has grown in popularity over the last several years.

Hydreight recently launched an updated app so that the hundreds of nurses on its platform can have a more streamlined experience. Often referred to as "Uber for nurses," the platform allows nurses be their own boss and work as independent 1099 contractors.

By creating a marketplace that empowers consumers to choose the right health care coverage for their unique and individual needs, CMS will continue to put consumers first and strengthen Medicare Advantage, already the chosen program of America’s seniors.

Electronic Clinical Outcomes Assessment and digital health tools were well-suited to accommodate the rapid rise of virtual and telehealth shifts during the Covid-19 pandemic and there is no going back. The adoption of eCOA technology in mental healthcare research can make pivotal advancements in mental health patient care.

There’s a lingering misperception among many patients, loved ones, and even healthcare professionals that hospice care is useful only in a patient’s last days or weeks of life.

Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.

Providers are, in many cases, getting the equivalent of a Russian nesting doll of third-party risks whenever they acquire a complex new technology solution. Cybersecurity supply chain risk management is the process of identifying and mitigating potential risks that may arise from these third-party products and services within an organization's IT infrastructure.

Atacicept, a Vera Therapeutics drug in development for the rare kidney disease immunoglobulin A nephropathy, is on its way to a pivotal test after achieving the main goal of a mid-stage clinical trial. But the results still fall short of data recently reported by a competitor that is addressing the same disease target.

Withings announced that it is developing a miniaturized platform that can analyze urine at home. The device, called U-Scan, sits within a toilet bowl and assesses specific biomarkers found in urine.